Target Information

Target General Infomation
Target ID
T45593
Former ID
TTDI01945
Target Name
Microtubule-associated protein tau
Gene Name
MAPT
Synonyms
Neurofibrillary tangle protein; PHFtau; Paired helical filamenttau; MAPT
Target Type
Clinical Trial
Disease Alzheimer disease [ICD9: 331; ICD10: G30]
Central nervous system disease [ICD10: G00-G99]
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3]
Neurodegenerative disease [ICD9: 330-337; ICD10: G30-G32]
Function
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N- terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. {ECO:0000269|PubMed:21985311}.
UniProt ID
P10636
Sequence
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPG
SETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAG
HVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEG
GRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPA
QDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLE
FTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPA
AAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSS
DPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQK
GQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREP
KKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLD
LSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEK
LDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDT
SPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL
Drugs and Mode of Action
Drug(s) Davunetide intranasal spray Drug Info Phase 3 Cognitive disorders [531616]
LMT-X Drug Info Phase 3 Alzheimer disease [549271]
PBT-2 Drug Info Phase 2 Alzheimer disease [523892]
Tau-binding PET tracer Drug Info Phase 2 Alzheimer disease [525148]
PTI-80 Drug Info Phase 1 Alzheimer disease [548777]
Modulator AL-408 Drug Info [531616]
BLV-0703 Drug Info [531616]
Davunetide intranasal spray Drug Info [531616]
NI-105 Drug Info [531616]
PBT-2 Drug Info [530731], [531616]
ReS8-T compounds Drug Info [531616]
Tau-binding PET tracer Drug Info [531616]
Inhibitor LMT-X Drug Info [531616], [550088]
PTI-80 Drug Info [531616], [551508]
Tau phosphorylation inhibitors Drug Info [531616]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway MAPK signaling pathway
Alzheimer&#039
s disease
NetPath Pathway IL2 Signaling Pathway
EGFR1 Signaling Pathway
Pathway Interaction Database LPA receptor mediated events
Reelin signaling pathway
Reactome Caspase-mediated cleavage of cytoskeletal proteins
WikiPathways Notch Signaling Pathway
IL-2 Signaling Pathway
MAPK Signaling Pathway
Copper homeostasis
Kit receptor signaling pathway
BDNF signaling pathway
Integrated Pancreatic Cancer Pathway
Alzheimers Disease
Regulation of Microtubule Cytoskeleton
Apoptotic execution phase
IL-5 Signaling Pathway
References
Ref 523892ClinicalTrials.gov (NCT01590888) Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease. U.S. National Institutes of Health.
Ref 525148ClinicalTrials.gov (NCT02414347) F 18 T807 Tau PET Imaging of Alzheimer's Disease. U.S. National Institutes of Health.
Ref 531616Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
Ref 548777Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028705)
Ref 549271Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034429)
Ref 530731PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
Ref 531616Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
Ref 550088Clinical pipeline report, company report or official report of TauRx.
Ref 551508Biopharmaceutical Research Companies Are Developing More Than 430 Medicines for Top Chronic Diseases Affecting Older Americans. Pharmaceutical Research and Manufacturers of America report. 2014.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.